Vor Biopharma Inc（VOR）の株式分析VORVor Biopharma Inc

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Vor Biopharma Inc is currently not a strong buy due to its recent price decline and negative earnings, but it has potential upside based on analyst targets. The current price is $18.03, which is below the analyst target of $27, indicating a possible upside of 49.5%. However, the RSI is at 34.261, suggesting the stock is oversold, and the company reported a significant loss of $1.57 billion in Q2 2025, which raises concerns about its financial health.